bioRxivCell Biology
Phosphorylation Status Of MUS81 Is A Modifier Of Olaparib Sensitivity In BRCA2-Deficient Cells
F. Blandino, E. Malacaria, C. Figlioli, A. Noto, G. M. Pugliese, A. Franchitto, P. Pichierri
Abstract
The MUS81 complex is crucial for preserving genome stability through resolution of branched DNA intermediates in mitosis and also for the processing of deprotected replication forks in BRCA2-deficient cells. Because of the existence of two different MUS81 complexes in mammalian cells that act in M or S-phase, whether and how the PARPi sensitivity of BRCA2-deficient cells is affected by loss of MUS81 function is unclear. Here, using a mutant of MUS81 that impairs its function in M-phase, we show that viability of BRCA2-deficient cells but not their PARPi sensitivity requires a fully-functional MUS81 complex in mitosis. In contrast, expression of a constitutively-active MUS81 is sufficient to confer PARPi resistance. From a mechanistic point of view, our data indicates that deregulated action of the mitotic active form of MUS81 in S-phase leads to the cleavage of stalled replication forks before their reversal, bypassing fork deprotection, and engaging a Pol{theta}-dependent DSBs repair. Collectively, our findings describe a novel mechanism leading to PARPi resistance that involves unscheduled MUS81-dependent cleavage of intact, unreversed replication forks. Since this cleavage occurs mimicking the phosphorylated status of S87 of MUS81, our data suggest that hyperphosphorylation of this residue in S-phase might represent a novel biomarker to identify resistance to PARPi.
- organism: human
- assay: DNA methylation
- assay: proteomics
- research focus: drug response / drug discovery
- research focus: cell signaling & trafficking
- research focus: chromatin & epigenetic regulation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- STN1 upregulation promotes PARPi resistance in BRCA2-deficient cancer cells via replication fork protection and suppression of ssDNA gap formation
Zubair Ahmed Laghari, Na Li, … Weihang Chai·NAR CancerPeer-reviewed·Jul 27, 2026
- MDC1 counteracts restrained replication fork restart and its loss causes chemoresistance in BRCA1/2-deficient mammary tumors
Martin Liptay, Joana S. Barbosa, … Sven Rottenberg·bioRxiv·Aug 18, 2022
- CHK2 regulates MUS81-dependent DSBs in response to replication stress and BRCA2 deficiency
E. Malacaria, C. Figlioli, … P. Pichierri·bioRxiv·Oct 8, 2022
- Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells
K. E. Clements, T. Thakar, … G.-L. Moldovan·bioRxiv·Apr 3, 2018
- BRCA2 reversion mutation-independent resistance to PARP inhibition in prostate cancer through loss of function perturbations in the DNA pre-replication complex
Kyrie Pappas, Matteo Ferrari, … Charles L. Sawyers·bioRxiv·Apr 20, 2025
- Synergistic effects of PARP inhibitors by Schlafen 11 and BRCA2-deficiency through accumulation of single-strand DNA gaps behind a fork